2023-06-16 22:00:00
Tingting, an 11-year-old girl, suffered from childhood B-cell acute lymphoblastic leukemia and was treated at National Taiwan University Hospital, becoming the first successful case of CAR-T cell therapy in Taiwan. (Photo/Provided by National Taiwan University Hospital)
Cell therapy has become the new savior in the fight once morest cancer! International research institutes pointed out that the business opportunity of CAR-T cell therapy will be as high as 219 million US dollars in 2022, and it is estimated that it will double to 643 million US dollars in 10 years. -T treatment, animal experiments have shown that nearly 90% of lung cancer, breast cancer, and colorectal cancer cells can disappear, and the survival time can be extended by 3 to 5 times. However, the “Regenerative Medicine Act” must be passed before the treatment can be applied.
71-year-old Mr. Cai suffers from diffuse large B-lymphocyte carcinoma. Due to the high degree of malignancy of the tumor, several times of chemotherapy and targeting failed to obtain good results. After discussing with doctors, he decided to accept CAR-T in February this year. Cell therapy (full name “chimeric antigen receptor T-cell therapy”, Chimeric antigen receptor T-cell therapy).
Dr. Ye Shipeng, deputy director of the Internal Medicine Department of the Affiliated Hospital of China Medical University, told the CTWANT reporter that the immune T cells in Mr. Cai’s blood were first concentrated and frozen, and then transported to the cell factory in Switzerland at low temperature throughout the whole process. The CAR-T cell army was then transported back to Taiwan by cold chain, and then transfused back into Mr. Cai’s body. One month following the CAR-T transplantation, Mr. Cai’s cancer cells were “zero detected” by precise tracking with positron emission tomography.
Ye Shipeng said that according to clinical research results, more than 50% of refractory or relapsed “diffuse large B-cell lymphoma” cancer cells will be wiped out through CAR-T cell therapy, and following more than 2 years of follow-up, there is a therapeutic response There are still 60% of patients without recurrence. Since the National Taiwan University Hospital took the lead in providing CAR-T cell therapy in 2022, many medical centers such as Sanzong, Rongzong, the Affiliated Hospital of China Medical University, and Hualien Tzu Chi Hospital now have this course of treatment.
Although the effect of CAR-T treatment is good, the whole course of treatment will cost regarding 12 million to 15 million at its own expense. In addition, the patient’s own cells need to be used, and the cells will be sent abroad to make a tailor-made treatment. The waiting time is at least two months. Patients can’t wait, and the quality of cells in terminally ill patients may not be good. Most importantly, CAR-T therapy is currently limited to blood cancers. Zhou Deyang, dean of the Affiliated Hospital of China Medical University and director of the Cell Therapy Translation Center, said that more than 90% of cancer patients are solid tumors, such as lung cancer, colorectal cancer, breast cancer, etc. Solid cancer cells are like a castle, and immune cells are difficult to invade. In the same tumor, the antigen expression of each cell may be different, so single-target CAR-T cells cannot effectively eliminate cancer cells.
After nearly 20 years of hard work, Zhou Deyang and his research team have developed “Allogeneic Transplantation, Non-viral Gene Modified Multi-targeted Nanobody-CAR.BiTE-gdT Immune Cell Therapy”. Transplantation of CAR-T therapy, the patient will be used immediately on the day following the test is completed, CAR.BiTE-gdT cell therapy can effectively penetrate into the solid cancer, and secrete BiTE (dual-directed T-cell activation antibody) to activate peripheral immune cells to jointly fight once morest cancer cells, In lung cancer and triple-negative breast cancer mouse models, the survival time was effectively prolonged by 3 to 5 times, and even cancer cells almost disappeared for a period of time. However, the cost of CAR.BiTE-gdT can be reduced to regarding one-fifth under the automated mass production process.
The research results were accepted for publication in the authoritative international journal “Advanced Science” in March this year, and are currently undergoing patent review in the United States and other countries, and the technology has been transferred to a biotechnology company. It is expected to start clinical trials within this year and be applied to lung cancer, Treatment of patients with cancers such as colorectal cancer and triple-negative breast cancer. However, since this therapy requires “allogeneic transplantation,” the draft of the “Regenerative Medicine Law” must be passed before it can be applied to treatment in the future.
1686962551
#Cancer #2Cell #Therapy #Works #Survival #Period #Major #Cancers #Increased #Times #Super #Money #Printing #Machine #OneYear #Business #Opportunity #Million #Live #CTWANT
